Category: Researcher Profiles
... support funding including a recent NHMRC Ideas grant exploring novel drug targets in leukemia. He has received over 3 million dollars in ... discovery that Venotoclax was a viable effective oral anti-leukemic drug. The results of this trial, led by Dr Enjeti at the Calvary Mater ... is to develop new drugs which are easily administered and have less toxicity than conventional chemotherapy. I am also involved with my ...
Category: News & Articles
... to buy and try cannabis. If the patient confides after taking the drug, as doctors we advise that it’s illegal and can’t be condoned, ... left unturned in the design of the trial – the way we selected the drug and the method we’re using to administer it. Two mathematicians ... paranoid or delusional. We don’t want patients getting unwell from toxicity and other side effects. This will be the first study of its ...
Category: News & Articles
... fluoropyrimidine and irinotecan dose personalisation to reduce severe toxicity. Fluoropyrimidines and irinotecan are anticancer drugs which, even at standard doses, cause severe toxicity leading to hospitalisation, ICU admission or death in 20-30 per ... genes responsible for metabolism of these drugs are responsible for toxicity in a proportion of cases. Professor Scott and his team’s ...
Category: Research
... however, they are highly toxic and 12% of children die due to toxicity associated with these treatments. Many children who are treated ...
Category: News & Articles
... dosing, with EKUT (Germany) in the combined role of therapeutic drug monitoring (TDM) and pharmacogenetics to individualise choice and ... targeted cancer therapies, dosing in neonates and therapeutic drug monitoring in clinical care including with antimicrobial therapies. ... the late Dorothy Ruth Frost. Awarded to Dr Anoop Enjet i | Predicting toxicity for myeloma therapy. HMRI Cancer Project Grant Supported by the ...
Category: Research
... required that efficiently kill AML cells, but have lower levels of toxicity, so that outcomes and the quality of life of AML patients can be improved. The researchers have developed a drug that targets an important protein in AML patients. This drug kills AML cells, including cells that are resistant to existing ...
Category: News & Articles
... acute myeloid leukaemia is just 24 per cent, and the development of drug resistance is common. New anti-cancer targets need to be identified ... to improve the outcomes without increasing side effects and toxicity.” At the recent 2013 HMRI Awards Night, Dr Skelding received further funding to investigate the effectiveness of a new drug she has developed for acute myeloid leukaemia. It is currently ...
Category: Research
... as well as cell sensitivity to chemotherapeutics. We have developed a drug (called C310) that targets BAALC. This drug kills a range of cancer cells (primarily leukaemia, breast and ... will possibly reduce treatment-associated side-effects and toxicity. Furthermore, we have shown that the sensitivity of cells to ...
Category: Research
... as well as cell sensitivity to chemotherapeutics. We have developed a drug (called C310) that targets BAALC. This drug kills a range of cancer cells (primarily leukaemia, breast and ... will possibly reduce treatment-associated side-effects and toxicity. Furthermore, we have shown that the sensitivity of cells to ...
Category: Researcher Profiles
... all anti-cancer medications and radiotherapy are associated with toxicity to the heart or blood vessels. This means patients with cancer ... of the mechanisms of how this works is poor, our ability to diagnose toxicity early is limited and treatment options are not personalised. ... Why did you get into research? I began my career as a hospital and drug information pharmacist and had direct exposure to people suffering ...